Across TCGA pan-cancer cohorts, GOLPH3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GOLPH3 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GOLPH3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLPH3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
HNSC, ESCA, and BLCA are the cancer types where GOLPH3 Mutation most reproducibly stratifies survival.